Rheumtaology Advisor offers featured news, research updates, and treatment guidelines to Rheumatology healthcare professionals.

9 小时之前 · The incidence rates of NMSC among patients with psoriasis ranged between 0.100 and 0.284 per 100 person-years. Patients with psoriasis on long-term TNFi treatment were not at increased risk for NMSC relative to the general population (SIR, 1.301; 95% CI, 0.676-2.502; I 2 =88.0%; P =.431). However, in the subgroup analysis, patients with psoriatic arthritis were at higher risk for NMSC (SIR, 1. ...

2022年4月6日 · References. American College of Rheumatology & American Association of Hip and Knee Surgeons. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip …

2021年6月18日 · The American College of Rheumatology (ACR) recently released updated guidelines for the pharmacologic management of rheumatoid arthritis (RA). The full report has been published simultaneously in Arthritis Care & Research and Arthritis & Rheumatology.. Overall, the updated guidelines include treatment with disease-modifying antirheumatic drugs (DMARDs), including biologic DMARDs (bDMARDs) and ...

3 天之前 · credit: Getty Images Swamy Venuturupalli, MD, and Beth Darnall, PhD, discuss the emerging field of digital therapeutics and their potential for managing chronic pain in rheumatic disease. Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a ...

2025年1月10日 · The transition from transient to persistent or chronic pain in rheumatology is heterogenous is nature. Overlapping pain conditions — such as fibromyalgia, endometriosis, migraine, and back pain — are often co-occurring, both with one another and with rheumatic diseases. 1 Rheumatology patients can present with localized and chronic widespread pain resulting from central sensitization.

2024年12月26日 · Patients with systemic autoimmune rheumatic diseases (SARDs) face higher risks for adverse events (AEs) when using sodium-glucose cotransporter-2 (SGLT2) inhibitors, compared against individuals without these conditions, according to study results published in Clinical Rheumatology.. As patients with SARDs are often excluded from certain clinical trials due to immunosuppressive therapies and ...

2024年3月5日 · Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs.

2021年4月30日 · In the United States, the lifetime risk of developing cancer is 1 in 3 individuals. 1 For patients with rheumatoid arthritis (RA), this risk may be increased due to the shared etiology between cancer and RA and the immunomodulatory nature of agents commonly used in RA treatment. 2 When determining appropriate therapeutic options for patients with RA and cancer, providers must make complex ...

2024年5月31日 · Upadacitinib is safe and effective for treating rheumatoid arthritis (RA) over 5 years, according to study results published in The Journal of Rheumatology.. The previously published SELECT-NEXT trial (ClinicalTrials.gov Identifier: NCT02675426) reported the safety and efficacy of upadacitinib up to 60 weeks, in terms of clinical and functional outcomes among patients with RA and an inadequate ...